Development and validation of a stability indicating assay of doxofylline by RP-HPLC: ESI-MS/MS, 1H and 13C NMR spectroscopic characterization of degradation products and process related impurities

被引:7
作者
Rao, R. Nageswara [1 ]
Naidu, Ch Gangu [1 ]
Prasad, K. Guru [1 ]
Santhakumar, B. [1 ]
Saida, Shaik [1 ]
机构
[1] Indian Inst Chem Technol, Div Analyt Chem, Discovery Lab, Hyderabad 500607, Andhra Pradesh, India
关键词
Anti-asthma; Doxofylline; Forced degradation; Related substances; Stability indicating assay; HUMAN SERUM; EXTRACTION;
D O I
10.1016/j.jpba.2013.02.004
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A validated stability indicating RP-HPLC assay of doxofylline was developed by separating its related substances and degradants on Lichrocart (R) C-18 (250 mm x 4.6 mm; 5 mu m) column using 10 mM ammonium acetate and acetonitrile as a mobile phase in a gradient mode of elution at a flow rate of 1.0 mL/min at 30 C. The column effluents were monitored by a photo diode array detector set at 274 nm. The method was validated in terms of accuracy, precision and linearity as per ICH guidelines. The limits of quantification of doxofylline and impurities were obtained in the range of 0.19-0.36 mu g/mL. Forced degradation of doxofylline was carried out under acidic, basic, thermal, photo, peroxide conditions and the degradation products were isolated and characterized by ESI-MS/MS, H-1 and C-13 spectroscopy. The method was successfully applied not only to quantify related substances and degradation products but also assay of doxofylline in bulk drugs. The recoveries of doxofylline and impurities were in the range of 99.00-100.05% and 97.83-99.86% respectively. (C) 2013 Elsevier B.V. All rights reserved.
引用
收藏
页码:92 / 99
页数:8
相关论文
共 17 条
[1]   ORAL AND INTRAVENOUS PHARMACOKINETIC PROFILES OF DOXOFYLLINE IN PATIENTS WITH CHRONIC-BRONCHITIS [J].
BOLOGNA, E ;
LAGANA, A ;
TERRACINO, D ;
BOLIGNARI, P ;
BIFFIGNANDI, P .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1990, 18 (04) :282-288
[2]  
CRAVANZOLA C, 1989, DRUG METAB DISPOS, V17, P437
[3]   ADENOSINE RECEPTORS IN THE CENTRAL NERVOUS-SYSTEM - RELATIONSHIP TO THE CENTRAL ACTIONS OF METHYLXANTHINES [J].
DALY, JW ;
BRUNS, RF ;
SNYDER, SH .
LIFE SCIENCES, 1981, 28 (19) :2083-2097
[4]   Doxofylline: A new generation xanthine bronchodilator devoid of major cardiovascular adverse effects [J].
Dini, FL ;
Cogo, R .
CURRENT MEDICAL RESEARCH AND OPINION, 2001, 16 (04) :258-268
[5]  
Duan J.L., 1996, CHIN PHARM J, V31, P99
[6]   DOXOFYLLINE EXERTS A PROPHYLACTIC EFFECT AGAINST BRONCHOCONSTRICTION AND PLEURISY INDUCED BY PAF [J].
FRANZONE, JS ;
CIRILLO, R ;
BIFFIGNANDI, P .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1989, 165 (2-3) :269-277
[7]  
FREDHOLM BB, 1985, ACTA MED SCAND, V217, P149
[8]  
Gannu R, 2007, ACTA CHROMATOGR, V19, P149
[9]  
Guo H., 1997, Yaoxue Xuebao, V32, P81
[10]  
Kamila MM, 2007, INDIAN J CHEM TECHN, V14, P523